Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238828 | 0.85 | CNR2 (0.54) | CNR2CNR1KDM4EALDH1A1 | |
| SCHEMBL5235836 | 0.84 | CNR2 (0.63) | CNR2CNR1MGLLL3MBTL1 | |
| SCHEMBL5238912 | 0.84 | CNR2 (0.56) | CNR2CNR1KDM4EMEN1KMT2A | |
| SCHEMBL5238753 | 0.84 | DRD4 (0.55) | CNR2HTR1ADRD4HTR2ASLC6A4 | |
| SCHEMBL3442195 | 0.83 | GPR119 (0.59) | HTR1ADRD4HTR2ASLC6A4DRD3 | |
| SCHEMBL16773016 | 0.83 | CNR2 (0.69) | CNR2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL3442393 | 0.82 | MGLL (0.58) | CNR2HTR1ADRD4HTR2ASLC6A4 | |
| SCHEMBL5623553 | 0.80 | KDM4E (0.59) | MGLLKDM4EL3MBTL1KCNH2 | |
| SCHEMBL5236404 | 0.80 | PKM (0.47) | CNR2CNR1KDM4EALDH1A1MAPK1 | |
| SCHEMBL5239769 | 0.80 | EGLN1 (0.49) | CNR2KDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403250-B1 | BIS(5-ARYL-2-PYRIDYL) DERIVATIVE | KOWA CO (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-7196101-B2 | Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases | KOWA CO., LTD (JP) | 2007-03-27 | — | — | US | disclosed |
| US-7196101-B2 | Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases | KOWA CO., LTD (JP) | 2007-03-27 | — | — | US | disclosed |
| US-7196101-B2 | Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases | KOWA CO., LTD (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1403250-A1 | BIS(5-ARYL-2-PYRIDYL) DERIVATIVE | Kowa Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6706703-B2 | BIS(5-ARYL-2-PYRIDYL) COMPOUND HAVING EXCELLENT IMMUNOGLOBULIN (IGE) ANTIBODY PRODUCTION INHIBITING ACTIVITY, USEFUL FOR THE PREVENTION OR TREATMENT OF ALLERGIC IMMUNE DISEASES | KOWA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | H1-0, BRD4, PAH | CNR2 76/4885HTR1A 504/4885DRD4 885/4885 |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | AHR, PAH, H1-0 | CNR2 309/4885HTR1A 229/4885DRD4 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.